Clinical Trials
13 trialsNCT07601399 2026-05-22
An EAP Treatment Protocol of Zipalertinib
Taiho Oncology, Inc.
Available
NCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT06810141 2026-05-14
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
ImmunityBio, Inc.
Available
NCT06834074 2026-05-14
NVL-655-EAP
Nuvalent Inc.
Available
NCT04571229 2026-05-11
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma
Memorial Sloan Kettering Cancer Center
Available
NCT05028166 2026-05-08
Individual Patient Compassionate Use of Mirdametinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Available
NCT05041036 2026-05-08
Individual Patient Compassionate Use of Nirogacestat
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Available
NCT06915766 2026-05-08
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT06948955 2026-05-08
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Available
NCT07573215 2026-05-07
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
Revolution Medicines, Inc.
Available
NCT05572970 2026-05-06
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Agenus Inc.
Available
NCT07535359 2026-05-06
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Daiichi Sankyo
Available
NCT06761976 2026-05-05
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
Bayer
Available